-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, InOOCSQY0i28crrvs8mZTnFbD+BWgigqi8Wa2hediCxTYN8PYkFUcBjgNS9pZQ6q uy9CT1VVvHbF5wzqoZr0Ag== 0001193125-08-028714.txt : 20080213 0001193125-08-028714.hdr.sgml : 20080213 20080213105211 ACCESSION NUMBER: 0001193125-08-028714 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20080213 DATE AS OF CHANGE: 20080213 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: PHARMACEUTICAL PRODUCT DEVELOPMENT INC CENTRAL INDEX KEY: 0001003124 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 561640186 STATE OF INCORPORATION: NC FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-48083 FILM NUMBER: 08601627 BUSINESS ADDRESS: STREET 1: 929 NORTH FRONT STREET CITY: WILMINGTON STATE: NC ZIP: 28401 BUSINESS PHONE: 9102510081 MAIL ADDRESS: STREET 1: 929 NORTH FRONT STREET CITY: WILMINGTON STATE: NC ZIP: 28401 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: ESHELMAN FREDRIC N CENTRAL INDEX KEY: 0001033409 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: BUSINESS PHONE: 9102510081 MAIL ADDRESS: STREET 1: PPD INC STREET 2: 929 NORTH FRONT STREET CITY: WILMINGTON STATE: NC ZIP: 28401 SC 13G/A 1 dsc13ga.htm SCHEDULE 13G AMENDMENT NO. 3 Schedule 13G Amendment No. 3

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13G

 

Under the Securities Exchange Act of 1934

(Amendment No. 3)*

 

 

 

 

Pharmaceutical Product Development, Inc.

(Name of Issuer)

 

 

Common Stock

(Title of Class of Securities)

 

 

717124101

(CUSIP Number)

 

 

December 31, 2007

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

x Rule 13d-1(b)

¨ Rule 13d-1(c)

¨ Rule 13d-1(d)

 

 

*   The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP Number: 717124101   Page 1

 

  (1)  

Names of reporting Persons. S.S. or IRS. Identification Nos. of Above Persons.

 

            Fredric N. Eshelman

    
  (2)  

Check the Appropriate Box if a Member of a Group: NOT APPLICABLE

(a)  ¨

(b)  ¨

    
  (3)  

SEC Use Only:

 

    
  (4)  

Citizenship or Place of Organization:

 

            United States

    

 

Number of  

Shares  

Beneficially  

Owned:

 

  

  (5)    Sole Voting Power:

 

            8,564,415

 

  (6)    Shared Voting Power:

 

            0

 

  (7)    Sole Dispositive Power:

 

            8,564,415

 

  (8)    Shared Dispositive Power:

 

            0

  (9)  

Aggregate Amount Beneficially Owned by Each Reporting Person:

 

            8,564,415

    
(10)  

Check if the Aggregate amount in Row (9) Excludes Certain Shares:  ü

 

    
(11)  

Percent of Class Represented by Amount in Row (9):

 

            7.2%

    
(12)  

Type of Reporting Person:

 

            IN

    

Page 2

 

Item 1.   Issuer      
 

(a)

    Pharmaceutical Product Development, Inc.      
 

(b)

   

929 North Front Street

Wilmington, North Carolina 28401

      
Item 2.   Person Filing      
 

(a)

    Fredric N. Eshelman      
 

(b)

   

Pharmaceutical Product Development, Inc.

929 North Front Street

Wilmington, North Carolina 28401

      
 

(c)

    United States      
 

(d)

    Common Stock      
 

(e)

    717124101      
Item 3.   Filing Pursuant to Rules 13d-1(b) or 13(d)-2(b)   
  Not Applicable   

Page 3

 

Item 4.    Ownership      
   (a)    8,564,415 includes 497,499 shares issuable pursuant to vested options.      
   (b)    7.2%      
   (c)    The Reporting Person retains sole voting and dispositive power of all shares.      
Item 5.    Ownership of Five Percent or Less of Class   
   Not Applicable   
Item 6.    Ownership of More than Five Percent on Behalf of Another Person      
   Not Applicable      
Item 7.    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company
   Not Applicable
Item 8.    Identification and Classification of Members of the Group      
   Not Applicable      
Item 9.    Notice of Dissolution of Group      
   Not Applicable      
Item 10.    Certification      
  

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

Page 4

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

February 13, 2008
Date  
Fredric N. Eshelman

/s/ Lisa C. Noecker

Name:  

Lisa C. Noecker

Title:   Attorney in Fact*

 

* Signed pursuant to a power of attorney, dated February 1, 2007, included as an exhibit to Schedule 13G filed with the Securities and Exchange Commission by Fredric N. Eshelman on February 13, 2008.

POWER OF ATTORNEY

KNOW ALL MEN BY THESE PRESENTS, that the undersigned hereby (1) revokes the general power of attorney granted to Rudy C. Howard and Fred B. Davenport, Jr. on December 16, 1998 with power for executing and filing of Securities Exchange Act of 1934 (the “Act”) Schedule 13G Beneficial Ownership Reports; and (2) constitutes and appoints each of B. Judd Hartman or Lisa C. Noecker signing singly, with full power of substitution, his/her true and lawful attorney-in-fact, to execute and cause to be filed and/or delivered, as required under Section 13(d) of the “Act” and the regulations thereunder, any number, as appropriate, of original, copies, or electronic filings of the Securities and Exchange Commission Schedule 13G Beneficial Ownership Reports (together with any amendments and joint filing agreements under Rule 13-d-1(f) (1) of the Act, as may be required thereto) to be filed and/or delivered with respect to any equity security (as defined in Rule 13(d)-1(d) under the Act) of Pharmaceutical Product Development, Inc. beneficially owned by the undersigned and which must be reported by the undersigned pursuant to Section 13(d) of the Act and the regulations thereunder, and generally to take such other actions and perform such other things necessary to effectuate the foregoing as fully in all respects as if the undersigned could do if personally present.

This Power of Attorney is governed by and shall be construed in accordance with the laws of the State of North Carolina. This Power of Attorney is effective until revoked by the undersigned, which revocation shall be evidenced by an instrument in writing in form required by North Carolina law. This Power of Attorney is executed pursuant to the provisions of the North Carolina General Statutes, Chapter 32A, Article 2, with the intention that this Power of Attorney and the authority of said attorney-in-fact hereunder shall continue in effect notwithstanding any incapacity or mental incompetence which may be incurred by the undersigned subsequent to the execution of this Power of Attorney by the undersigned.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 1st day of February, 2007.

 

/s/ Fredric N. Eshelman
 -----END PRIVACY-ENHANCED MESSAGE-----